{"id":5281,"date":"2022-10-04T19:14:31","date_gmt":"2022-10-04T17:14:31","guid":{"rendered":"https:\/\/www.amyloidosisalliance.org\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/"},"modified":"2026-11-03T10:46:27","modified_gmt":"2026-11-03T09:46:27","slug":"sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering","status":"publish","type":"post","link":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/","title":{"rendered":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering"},"content":{"rendered":"\n<h2> Det 18:e internationella symposiet om amyloidos, \u201d<a href=\"https:\/\/www.isaamyloidosis.org\">ISA<\/a>\u201d, av Ben Woltering.<\/h2><p>Symposiet h\u00f6lls den 4-8 september 2022 i Heidelberg i Tyskland.<\/p><p>Det \u00e4r en v\u00e4rldskongress om amyloidos f\u00f6r all v\u00e5rdpersonal, forskare och l\u00e4kemedelsindustrin, som h\u00e5lls vartannat \u00e5r n\u00e5gonstans i v\u00e4rlden.<\/p><p>I \u00e5r h\u00f6lls den vid universitetet i Heidelberg i Tyskland. D\u00e4r fanns omkring 1 100 deltagare fr\u00e5n \u00f6ver 50 l\u00e4nder, och tack vare goda kontakter mellan ISA och alliansen deltog ocks\u00e5 ett begr\u00e4nsat antal patienter.<\/p><p>Alla f\u00f6ljde direkt (25 % online) de heldagsl\u00e5nga sessionerna och diskuterade de senaste och b\u00e4sta id\u00e9erna f\u00f6r att bek\u00e4mpa alla typer av amyloidos.<\/p><p>Det var inte bara h\u00e5rt arbete, det fanns ocks\u00e5 trevliga inslag som v\u00e4lkomstmottagning, kongressmiddag, prisceremoni och f\u00f6rst\u00e5s tid f\u00f6r n\u00e4tverkande.<\/p><h2>Ett mycket intressant program<\/h2><p>Det var mycket intressant att f\u00e5 veta vilka l\u00e4kemedel som \u00e4r p\u00e5 v\u00e4g f\u00f6r att stabilisera, bota eller till och med f\u00e5 sjukdomen att g\u00e5 tillbaka. M\u00e5nga muntliga presentationer och f\u00f6rel\u00e4sningar handlade om detta. Alla typer av amyloidos togs upp.<\/p><p>M\u00e5nga av deltagarna var unga och mycket lovande forskare.<br \/>De presenterade ofta mycket grundl\u00e4ggande och viktig forskning i form av posters (309 presentationer!). J\u00e4mf\u00f6rt med tidigare m\u00f6ten fanns ett mycket st\u00f6rre intresse f\u00f6r betydelsen av DNA och immunologiska tekniker. Till exempel: \u00e5ldrande inneb\u00e4r ocks\u00e5 att immunsystemet \u00e5ldras (T-celler, makrofager). Ett annat exempel: riktad genterapi (CRISPR-Cas9) kan leda till &gt;95 % tillbakag\u00e5ng.<\/p><p>H\u00e4r nedan f\u00f6ljer fler resultat och viktiga punkter.<\/p><h2>N\u00e5gra \u00e4mnen inom grundforskningen:<\/h2><p>Genetik som riskfaktor f\u00f6r att utveckla amyloidos.<br \/>Spelar N-glykosylering av den l\u00e4tta kedjan en roll f\u00f6r amyloidbildningen?<br \/>Bel\u00e4gg f\u00f6r att l\u00e4tta kedjor \u00e4r kardiotoxiska vid AL-amyloidos<br \/>Kollagen som \u00e4r kopplat till AL-amyloidos h\u00e4mmar fagocytosen av fibriller<\/p><h2>N\u00e5gra \u00e4mnen inom den kliniska forskningen:<\/h2><p>Artificiell intelligens och maskininl\u00e4rning b\u00f6rjar anv\u00e4ndas i diagnostiken.<br \/>Gener som riskfaktor f\u00f6r att insjukna, f\u00f6r prognosen (AL) och som v\u00e4gledning f\u00f6r behandlingen.<br \/>Ett nytt begrepp vid AL-amyloidos: minimal\/m\u00e4tbar kvarvarande sjukdom (MRD)<br \/>Neurofilament l\u00e4tt kedja \u00e4r en biomark\u00f6r i serum f\u00f6r neuropati<br \/>\u00d6kad leverstelhet \u00e4r en mark\u00f6r f\u00f6r amyloid i levern.<br \/>Bilddiagnostik vid amyloidos: f\u00f6r att uppt\u00e4cka sjukdomen, bed\u00f6ma sv\u00e5righetsgraden och f\u00f6lja f\u00f6rloppet.<br \/>1241-AT01 \u00e4r ett nytt lovande sp\u00e5r\u00e4mne vid amyloidos<\/p><h2>Nya eller m\u00f6jliga behandlingsformer:<\/h2><p>\u2022 AL: BCL-2-h\u00e4mmaren venetoklax, belantamab mafodotin (anti-BCMA), BCMA-CAR-T, CAEL-101, elotuzumab (binder till SLAMF7), isatuximab (monoklonal antikropp mot CD38)<br \/>\u2022 ATTR: glavonoid (flavonoidolja fr\u00e5n lakrits), en naturlig tetramerstabilisator, eplontersen (antisens), acoramidis (AG10, stabilisator), NNC6019-0001 (antikropp som binder till all TTR utom nativ TTR) <br \/>\u2022 All amyloid: antikroppar, t.ex. birtamimab (NEOD001), AT-2 och AT-4 (fusionspeptider som binder till alla typer av amyloid), makrofager med kim\u00e4r antigenreceptor (CAR-M) som en m\u00f6jlig behandling f\u00f6r att avl\u00e4gsna amyloid <br \/>\u2022 Underst\u00f6djande behandling: droxidopa (prodrug till noradrenalin) mot ortostatisk hypotension, intraven\u00f6sa inotropa l\u00e4kemedel, hj\u00e4rttransplantation vid ATTRwt<\/p><h2>Ett lyckat symposium om amyloidos<\/h2><p>Alla deltagare var till slut \u00f6verens om att det hade varit ett fantastiskt och lyckat symposium, mycket v\u00e4l organiserat och med professorerna Sch\u00f6nland &amp; Hegenbart som v\u00e4rdar.<\/p><p>Vi ser alla fram emot n\u00e4sta ISA-m\u00f6te, i Rochester i USA, i juni 2024.<\/p><p>Sammanfattningen bygger ocks\u00e5 p\u00e5 information fr\u00e5n dr Bouke Hazenberg.<\/p><p>\u00a0<\/p><p><strong><em>Ben Woltering<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[93],"tags":[],"class_list":["post-5281","post","type-post","status-publish","format-standard","hentry","category-uncategorized-sv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering<\/title>\n<meta name=\"description\" content=\"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering\" \/>\n<meta property=\"og:description\" content=\"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-04T17:14:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T09:46:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/amyloidosisalliance.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/\"},\"author\":{\"name\":\"Amyloidosis Alliance\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#organization\"},\"headline\":\"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering\",\"datePublished\":\"2022-10-04T17:14:31+00:00\",\"dateModified\":\"2026-11-03T09:46:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/\"},\"wordCount\":588,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#organization\"},\"articleSection\":[\"Okategoriserat\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/\",\"name\":\"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#website\"},\"datePublished\":\"2022-10-04T17:14:31+00:00\",\"dateModified\":\"2026-11-03T09:46:27+00:00\",\"description\":\"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startsida\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/startsida\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering","description":"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/","og_locale":"sv_SE","og_type":"article","og_title":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering","og_description":"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.","og_url":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_published_time":"2022-10-04T17:14:31+00:00","article_modified_time":"2026-11-03T09:46:27+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/amyloidosisalliance.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_creator":"@amyloidosisa","twitter_site":"@amyloidosisa","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/#article","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/"},"author":{"name":"Amyloidosis Alliance","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#organization"},"headline":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering","datePublished":"2022-10-04T17:14:31+00:00","dateModified":"2026-11-03T09:46:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/"},"wordCount":588,"commentCount":0,"publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#organization"},"articleSection":["Okategoriserat"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/","url":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/","name":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#website"},"datePublished":"2022-10-04T17:14:31+00:00","dateModified":"2026-11-03T09:46:27+00:00","description":"Ben Woltering sammanfattar det 18:e International Symposium on Amyloidosis (ISA), som h\u00f6lls i Heidelberg i september 2022 med omkring 1 100 deltagare.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/sammanfattning-av-foredragen-och-hojdpunkterna-fran-isa-kongressen-av-ben-woltering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startsida","item":"https:\/\/www.amyloidosisalliance.org\/sv\/startsida\/"},{"@type":"ListItem","position":2,"name":"Sammanfattning av f\u00f6redragen och h\u00f6jdpunkterna fr\u00e5n ISA-kongressen, av Ben Woltering"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#website","url":"https:\/\/www.amyloidosisalliance.org\/sv\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/posts\/5281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/comments?post=5281"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/posts\/5281\/revisions"}],"predecessor-version":[{"id":5282,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/posts\/5281\/revisions\/5282"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/media?parent=5281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/categories?post=5281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/sv\/wp-json\/wp\/v2\/tags?post=5281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}